Trinity Biotech's FY2025 Annual Report: Going Concern Warning, Nasdaq Delisting Fight, and $115M Debt Maturity Loom
TRIB is trading near its 52-week low of $7.94 (14% above the low) on light trading volume (0.2× avg).
Summary
Trinity Biotech's FY2025 Annual Report reveals a $37.4M loss, going concern uncertainty from its auditor, a $115M debt maturity in January 2027 with no extension, and an ongoing Nasdaq delisting fight.
Key Events · Earnings and Guidance · TRIB
-
FY2025 Revenue Down 28.9%
Revenue fell to US$43.8M from US$61.6M in 2024, driven by a 53.5% drop in point-of-care sales (US$8.1M vs US$17.4M) due to HIV funding disruptions.
-
Net Loss Widens to $37.4M
Loss for the year was US$37.4M, up from US$31.8M in 2024, with financial expenses of US$21.3M including a US$10.0M loss on extinguishment of the old term loan.
-
Going Concern Uncertainty
Auditor Grant Thornton included a material uncertainty related to going concern, citing net current liabilities of US$105.3M and the US$115M Perceptive term loan maturing January 15, 2027 with no extension agreement reached.
-
Nasdaq Delisting Determination
Received August 28, 2026 for failing the MVPHS requirement; company requested a hearing September 4, 2026, which stays delisting pending the panel's decision (extension possible to February 24, 2027).
Analysis · TRIB · Life Sciences
The FY2025 Annual Report from Trinity Biotech confirms a precarious financial position. Revenue fell 28.9% to $43.8M while the net loss widened to $37.4M. The auditor's report includes a material uncertainty related to going concern, driven by a $115M Perceptive term loan maturing January 15, 2027 with no extension agreement in place, and a Nasdaq delisting determination received August 28, 2026 for failing the MVPHS requirement. The company has requested a hearing, which stays delisting pending the panel's decision, but the outcome is uncertain. This filing also reveals the company breached its minimum revenue covenant for Q4 2025 and has relied on repeated waivers and PIK interest arrangements from Perceptive to stay afloat. The AGM notice for September 30, 2026 includes routine auditor and director re-appointments, but the financial disclosures are the dominant story.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRIB was trading at $9.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $7.94 to $52.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.